TNYA
Tenaya Therapeutics, Inc.
Biotechnology
Market Cap$184M
5Y Perf.-94.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TNYA vs SGMO
Revenue, margins, valuation, and 5-year total return — side by side.
SGMO
Sangamo Therapeutics, Inc.
Biotechnology
Market Cap$22M
5Y Perf.-98.9%
TNYA vs SGMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TNYA | SGMO |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $184M | $22M |
| Revenue (TTM) | $0.00 | $33M |
| Net Income (TTM) | $-91M | $-109M |
| Gross Margin | — | 100.0% |
| Operating Margin | — | -331.6% |
| Total Debt | $11M | $31M |
| Cash & Equiv. | $101M | $42M |
TNYA vs SGMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TNYA
SGMO
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Tenaya Therapeutics… (TNYA) | 100 | 5.5 | -94.5% |
| Sangamo Therapeutic… (SGMO) | 100 | 1.1 | -98.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TNYA vs SGMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TNYA leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Sangamo Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TNYA
Tenaya Therapeutics, Inc.
The Long-Run Compounder
TNYA carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- -94.5% 10Y total return vs SGMO's -98.4%
- Lower volatility, beta 2.80, Low D/E 8.8%, current ratio 6.84x
- 11.8% revenue growth vs SGMO's -67.2%
Best for: long-term compounding and sleep-well-at-night
SGMO
Sangamo Therapeutics, Inc.
The Income Pick
SGMO is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.65
- Rev growth -67.2%, EPS growth 66.9%, 3Y rev CAGR -19.5%
- Beta 1.65, current ratio 1.13x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TNYA | 11.8% revenue growth vs SGMO's -67.2% |
| Quality / Margins | TNYA | 1.8% margin vs SGMO's -331.3% |
| Stability / Safety | SGMO | Beta 1.65 vs TNYA's 2.80 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TNYA | +88.6% vs SGMO's -84.4% |
| Efficiency (ROA) | TNYA | -70.0% ROA vs SGMO's -116.5%, ROIC -103.2% vs -178.8% |
TNYA vs SGMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
TNYA vs SGMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTNYALAGGINGSGMO
SGMOSangamo Therapeutics,…
0leads
TNYATenaya Therapeutics, …
3leads
6 Total Categories
CATEGORYLEADERvs SGMOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TNYA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TNYA8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
TNYA6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TNYA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SGMO and TNYA operate at a comparable scale, with $33M and $0 in trailing revenue.
| Metric | TNYATenaya Therapeuti… | SGMOSangamo Therapeut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $33M |
| EBITDAEarnings before interest/tax | -$93M | -$101M |
| Net IncomeAfter-tax profit | -$91M | -$109M |
| Free Cash FlowCash after capex | -$69M | -$76M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -3.3% |
| Net MarginNet income ÷ Revenue | — | -3.3% |
| FCF MarginFCF ÷ Revenue | — | -2.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -98.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +57.1% | -3.5% |
TNYA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — TNYA and SGMO each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | TNYATenaya Therapeuti… | SGMOSangamo Therapeut… |
|---|---|---|
| Market CapShares × price | $184M | $22M |
| Enterprise ValueMkt cap + debt − cash | $94M | $10M |
| Trailing P/EPrice ÷ TTM EPS | -1.44x | -0.21x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.37x |
| Price / BookPrice ÷ Book value/share | 1.05x | 0.90x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — TNYA and SGMO each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
TNYA leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
TNYA delivers a -85.2% return on equity — every $100 of shareholder capital generates $-85 in annual profit, vs $-8 for SGMO. TNYA carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to SGMO's 1.34x. On the Piotroski fundamental quality scale (0–9), TNYA scores 4/9 vs SGMO's 1/9, reflecting mixed financial health.
| Metric | TNYATenaya Therapeuti… | SGMOSangamo Therapeut… |
|---|---|---|
| ROE (TTM)Return on equity | -85.2% | -8.1% |
| ROA (TTM)Return on assets | -70.0% | -116.5% |
| ROICReturn on invested capital | -103.2% | -178.8% |
| ROCEReturn on capital employed | -79.3% | -119.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.09x | 1.34x |
| Net DebtTotal debt minus cash | -$90M | -$11M |
| Cash & Equiv.Liquid assets | $101M | $42M |
| Total DebtShort + long-term debt | $11M | $31M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
TNYA leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
TNYA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TNYA five years ago would be worth $553 today (with dividends reinvested), compared to $96 for SGMO. Over the past 12 months, TNYA leads with a +88.6% total return vs SGMO's -84.4%. The 3-year compound annual growth rate (CAGR) favors TNYA at -49.0% vs SGMO's -57.0% — a key indicator of consistent wealth creation.
| Metric | TNYATenaya Therapeuti… | SGMOSangamo Therapeut… |
|---|---|---|
| YTD ReturnYear-to-date | +15.4% | -77.0% |
| 1-Year ReturnPast 12 months | +88.6% | -84.4% |
| 3-Year ReturnCumulative with dividends | -86.7% | -92.0% |
| 5-Year ReturnCumulative with dividends | -94.5% | -99.0% |
| 10-Year ReturnCumulative with dividends | -94.5% | -98.4% |
| CAGR (3Y)Annualised 3-year return | -49.0% | -57.0% |
TNYA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TNYA and SGMO each lead in 1 of 2 comparable metrics.
Risk & Volatility
SGMO is the less volatile stock with a 1.65 beta — it tends to amplify market swings less than TNYA's 2.80 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TNYA currently trades 36.1% from its 52-week high vs SGMO's 13.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TNYATenaya Therapeuti… | SGMOSangamo Therapeut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.80x | 1.65x |
| 52-Week HighHighest price in past year | $2.35 | $0.77 |
| 52-Week LowLowest price in past year | $0.36 | $0.10 |
| % of 52W HighCurrent price vs 52-week peak | +36.1% | +13.2% |
| RSI (14)Momentum oscillator 0–100 | 57.3 | 38.1 |
| Avg Volume (50D)Average daily shares traded | 4.2M | 9.8M |
Evenly matched — TNYA and SGMO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TNYA as "Buy" and SGMO as "Hold". Consensus price targets imply 7064.0% upside for SGMO (target: $7) vs 174.6% for TNYA (target: $2).
| Metric | TNYATenaya Therapeuti… | SGMOSangamo Therapeut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $2.33 | $7.25 |
| # AnalystsCovering analysts | 6 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TNYA leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallTenaya Therapeutics, Inc. (TNYA)Leads 3 of 6 categories
Loading custom metrics...
TNYA vs SGMO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TNYA or SGMO a better buy right now?
Analysts rate Tenaya Therapeutics, Inc.
(TNYA) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TNYA or SGMO?
Over the past 5 years, Tenaya Therapeutics, Inc.
(TNYA) delivered a total return of -94. 5%, compared to -99. 0% for Sangamo Therapeutics, Inc. (SGMO). Over 10 years, the gap is even starker: TNYA returned -94. 5% versus SGMO's -98. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TNYA or SGMO?
By beta (market sensitivity over 5 years), Sangamo Therapeutics, Inc.
(SGMO) is the lower-risk stock at 1. 65β versus Tenaya Therapeutics, Inc. 's 2. 80β — meaning TNYA is approximately 70% more volatile than SGMO relative to the S&P 500. On balance sheet safety, Tenaya Therapeutics, Inc. (TNYA) carries a lower debt/equity ratio of 9% versus 134% for Sangamo Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TNYA or SGMO?
On earnings-per-share growth, the picture is similar: Sangamo Therapeutics, Inc.
grew EPS 66. 9% year-over-year, compared to 55. 0% for Tenaya Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TNYA or SGMO?
Tenaya Therapeutics, Inc.
(TNYA) is the more profitable company, earning 0. 0% net margin versus -169. 4% for Sangamo Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TNYA leads at 0. 0% versus -179. 9% for SGMO. At the gross margin level — before operating expenses — SGMO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TNYA or SGMO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TNYA or SGMO better for a retirement portfolio?
For long-horizon retirement investors, Sangamo Therapeutics, Inc.
(SGMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Tenaya Therapeutics, Inc. (TNYA) carries a higher beta of 2. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SGMO: -98. 4%, TNYA: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TNYA and SGMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.